Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Liao, Yunmei ^a   Ou, Juanjuan ^a   Deng, Jia ^a   Geng, Peiliang ^a   Zeng, Rui ^a   Tian, Yi ^a   Liang, Houjie ^a   Ni, Bing ^a   Ruan, Zhihua ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clinical relevance; Colorectal cancer; Lymphocyte subset; Tumor infiltrating lymphocytes

Indexed keywords

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; YOUNG ADULT; COLORECTAL TUMOR; IMMUNOLOGY; PATHOLOGY;

CD20 ANTIGEN;

AGED; ANTIGENS, CD20; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM METASTASIS;

EID: 84883610854     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0727-0     Document Type: Article

References (22)

1. Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, Kumar M, Jones S, Rees B, Williams G, et al. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut. 2012;61(8):1163-71.
2. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41(17):2645-54. (Pubitemid 41607555)
3. Leslie H, Sobin MKG. Christian Wittekind TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell; 2009.
4. Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84(4):981-7.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4. (Pubitemid 44498003)
6. Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol. 2008;108(1):106-11. (Pubitemid 350299430)
7. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH. CD20 + tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8 + T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281-92.
8. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405-13.
9. Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg. 2012;147(4):366-72.
10. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844-7. (Pubitemid 28331029)
11. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55(9):662-8. (Pubitemid 34970087)
12. Lee SJ, Lim HJ, Choi YH, Chang YH, Lee WJ, do Kim W, Yoon GS. The clinical significance of tumor-infiltrating lymphocytes and microscopic satellites in acral melanoma in a Korean population. Ann Dermatol. 2013;25(1):61-6.
13. Scurr M, Gallimore A, Godkin A. T cell subsets and colorectal cancer: discerning the good from the bad. Cell Immunol. 2012;279(1):21-4.
14. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012;72(23):6119-29.
15. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108(1):155-62.
16. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41(17):2645-54. (Pubitemid 41607555)
17. Vauleon E, Avril T, Collet B, Quillien V. Mosser J. Clin Dev Immunol: Overview of cellular immunotherapy for patients with glioblastoma; 2010. p. 2010.
18. Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, Takeishi K, Ijichi H, Harada N, Uchiyama H, et al. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J clin Oncol. 2010;15(6):552-8.
19. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol. 2004;191(5):1598-605. (Pubitemid 39491185)
20. Demotte N, Wieers G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010;70(19):7476-88.
21. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586-93. (Pubitemid 47041232)
22. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: working together to promote patient survival. Oncoimmunology. 2012;1(9):1623-5.